Here is a link to a news story with additional commentary about the closing of PFE's oligo research center:
http://www.genomeweb.com/rnai/pfizer-shut-down-oligo-therapeutics-unit-part-restructuring
While PFE could theoretically still partner with ISIS, ALNY, RXII, etc for oligo drugs, it seems less likely now- this is a dramatic about face from a company who only months ago was still talking about having a oligo candidate in the pipeline in 2011. In contrast, SNY and GSK have shown a willingness to partner with ISIS and its partially-owned affiliate Regulus. Further, SNY appears to be on the verge of acquiring GENZ and its interest in Mipomersin from ISIS, the most advanced antisense drug candidate in development.
http://www.genomeweb.com/rnai/pfizer-shut-down-oligo-therapeutics-unit-part-restructuring
While PFE could theoretically still partner with ISIS, ALNY, RXII, etc for oligo drugs, it seems less likely now- this is a dramatic about face from a company who only months ago was still talking about having a oligo candidate in the pipeline in 2011. In contrast, SNY and GSK have shown a willingness to partner with ISIS and its partially-owned affiliate Regulus. Further, SNY appears to be on the verge of acquiring GENZ and its interest in Mipomersin from ISIS, the most advanced antisense drug candidate in development.
RSS Feed
